Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase II/III Trial of Peri-Operative Chemotherapy With or Without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinomas and (in Selected Centres) MRI and PET/CT Sub-studies

NCT00450203 is registered in ClinicalTrials.gov with Professor David Cunningham as lead sponsor.

NCT NCT00450203
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00450203 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase II/III Trial of Peri-Operative Chemotherapy With or Without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinomas and (in Selected Centres) MRI and PET/CT Sub-studies
Lead sponsor
Professor David Cunningham
Phase
Phase 2/3
Overall status
Unknown status
Start date
October 31, 2007
Completion date
December 31, 2017
Enrollment
1,103 (estimated)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

oesophagogastric cancer